Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals presented 11 late-breaking data presentations at SLEEP 2026, highlighting real-world evidence for Xywav in treating narcolepsy and idiopathic hypersomnia.
Key figures
- Drug Name
- Xywav
- Phase Of Trial
- Phase 4
- Ih annual diagnoses us
- 28000
- Rems patients analyzed
- 13000
- Xywav sodium content mg
- 131
- Time to stable dose ih days
- 42.1
- Sodium reduction mg per night
- 1,000 to 1,500
- High sodium oxybate content mg
- 1640
- Time to stable dose narcolepsy days
- 41.8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.